{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T07:35:25Z","timestamp":1782113725331,"version":"3.54.5"},"reference-count":124,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2025,1,2]]},"DOI":"10.1080\/13543776.2024.2441658","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T18:40:17Z","timestamp":1734720017000},"page":"31-45","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["WD repeat domain 5 (WDR5) inhibitors: a patent review (2016-present)"],"prefix":"10.1080","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1842-9860","authenticated-orcid":false,"given":"Jesse A.","family":"Coker","sequence":"first","affiliation":[{"name":"Cleveland Clinic","place":["Cleveland, USA"]},{"name":"Cleveland Clinic Lerner College of Medicine of Case Western Reserve University","place":["Cleveland, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6332-1827","authenticated-orcid":false,"given":"Shaun R.","family":"Stauffer","sequence":"additional","affiliation":[{"name":"Cleveland Clinic","place":["Cleveland, USA"]},{"name":"Cleveland Clinic Lerner College of Medicine of Case Western Reserve University","place":["Cleveland, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,12,22]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb0709-678"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2205691119"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13550-2"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1528-1"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05780-8"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.159921"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2013.12.001"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.1.24"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0033-1343631"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.33"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01439.x"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2022.166600"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9312"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2016.488"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04329-y"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-020-00582-5"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2015.02.028"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/23723556.2019.1709388"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7020021"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2034-1"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.devcel.2017.05.023"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb1116"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/narcan\/zcac007"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa051"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b01608"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature15251"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2018.05.034"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.6b01796"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00502"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-023-00477-z"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.1859"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1910391116"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1101\/gad.349803.122"},{"issue":"5","key":"e_1_3_5_36_1","first-page":"7864","article-title":"Effect of high WDR5 expression on the hepatocellular carcinoma prognosis","volume":"15","author":"Cui Z","year":"2018","unstructured":"Cui Z, Li H, Liang F, et al. Effect of high WDR5 expression on the hepatocellular carcinoma prognosis. Oncol Lett. 2018 May;15(5):7864\u20137870.","journal-title":"Oncol Lett"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/jop.12708"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-0423"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-2797"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.05.063"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.26491"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.111"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep08293"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0124964"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2010.04.003"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0968-0004(99)01384-5"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-011-1018-1"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.364125"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108636"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1042\/BCJ20210253"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01589-z"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jproteome.7b00451"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.179"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c00037"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13010274"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1103-9"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.06.010"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-05947-9"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2019.02.047"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.90683"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00924-09"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2819"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-4087"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15153910"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1021\/ja306028q"},{"key":"e_1_3_5_66_1","unstructured":"University of Science and Technology of China. Polypeptide inhibitor targeting WDR5 (WD40 repeat protein-5) and application thereof in preparing antitumor drugs. CN115974965. 2023."},{"key":"e_1_3_5_67_1","unstructured":"The Regents of the University of Michigan. Inhibition of WDR5 interaction with its binding partners and therapeutic methods. WO2011159685. 2011."},{"key":"e_1_3_5_68_1","unstructured":"The Regents of the University of Michigan. Cyclized peptidomimetic small molecule inhibitors of the WDR5 and MLL1 interaction. WO2013082017. 2013."},{"key":"e_1_3_5_69_1","unstructured":"The Regents of the University of Michigan. Peptidomimetic inhibitors of the WDR5-MLL interaction. WO2018213228. 2018."},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20121280"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1021\/ml300467n"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b01630"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4580-6"},{"key":"e_1_3_5_74_1","unstructured":"Propellon Therapeutics. Inhibitors of WDR5 protein-protein binding. WO2019046944. 2019."},{"key":"e_1_3_5_75_1","unstructured":"Ontario Institute for Cancer Research (OICR). Inhibitors of WDR5 Protein-Protein Binding. WO2017147700. 2017."},{"key":"e_1_3_5_76_1","unstructured":"Propellon Therapeutics. Inhibitors of WDR5 Protein:Protein Binding. US20190119264. 2019."},{"key":"e_1_3_5_77_1","unstructured":"Celgene inks $1B deal for a preclinical epigenetic blood cancer drug from Canada. [cited 2024 Aug 29]. Available from: https:\/\/www.fiercebiotech.com\/biotech\/celgene-inks-1b-deal-for-a-preclinical-epigenetic-blood-cancer-drug-from-canada"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2016.09.073"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2016.08.036"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113677"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2016.04.032"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c00091"},{"key":"e_1_3_5_83_1","unstructured":"China Pharmaceutical University. Aniline WDR5 protein-protein interaction inhibitor preparation method therefor and use thereof. WO2020172932. 2020."},{"key":"e_1_3_5_84_1","unstructured":"China Pharmaceutical University. Phenyl triazole MLL1-WDR5 protein-protein interaction inhibitor. WO2019205687. 2019."},{"key":"e_1_3_5_85_1","unstructured":"Huyabio International LLC & China Pharmaceutical University. Phenyl triazole MLL1-WDR5 protein-protein interaction inhibitor. US20230286925. 2023."},{"key":"e_1_3_5_86_1","unstructured":"Huyabio International LLC. Haloalkyl pyridyl triazole MLL1-WDR5 protein-protein interaction inhibitor. US20230286948. 2023."},{"key":"e_1_3_5_87_1","unstructured":"Huyabio International LLC. Blood-brain barrier crossing MLL1-WDR5 protein-protein interaction inhibitor compounds and uses thereof. WO2023177592. 2023."},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.TARG-23-C071"},{"key":"e_1_3_5_89_1","unstructured":"Huyabio Development Compounds. 2024 [cited 2024 May 31]. Available from: https:\/\/huyabio.com\/pipeline\/"},{"key":"e_1_3_5_90_1","unstructured":"Gan & Lee Pharm Co. Ltd. Compound used as WDR5 inhibitor or pharmaceutically acceptable salt thereof and use of compound. WO2024002379. 2024."},{"key":"e_1_3_5_91_1","unstructured":"China Pharmaceutical University. Preparation of benzamide derivatives as WDR5 inhibitors. CN116354879. 2023."},{"key":"e_1_3_5_92_1","unstructured":"China Pharmaceutical University. Preparation of amide compound and their pharmaceutical application. CN105175284. 2015."},{"key":"e_1_3_5_93_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b00375"},{"key":"e_1_3_5_94_1","unstructured":"Vanderbilt University. WDR5 inhibitors and modulators. US20190084988. 2019."},{"key":"e_1_3_5_95_1","unstructured":"Vanderbilt University. WDR5 inhibitors and modulators. US20180086767. 2018."},{"key":"e_1_3_5_96_1","unstructured":"Vanderbilt University. Preparation of Iminoheterocyclylmethyl Benzamide and picolinamide derivatives as WDR5-MLL1 inhibitors and modulators. US20200102288. 2020."},{"key":"e_1_3_5_97_1","unstructured":"Vanderbilt University. Quinazolin-4(3H)-one 2 3-dihydroquinazolin-4(1H)-one 3 4-dihydrobenzo[f]1 4]oxazepin-5(2H)-one and 3 4-dihydro-1H-benzoe]1 4]diazepine-2 5-dione compounds as WDR5 inhibitors and modulators and their preparation. WO2020247679. 2020."},{"key":"e_1_3_5_98_1","unstructured":"Vanderbilt University. Preparation of WDR5 inhibitors and modulators. WO2021092525. 2021."},{"key":"e_1_3_5_99_1","unstructured":"Vanderbilt University. Quinazolin-4-yltetrahydroisoquinolin-1-one derivatives as WDR5 inhibitors and modulators. WO2022236101. 2022."},{"key":"e_1_3_5_100_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c01529"},{"key":"e_1_3_5_101_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2211297120"},{"key":"e_1_3_5_102_1","unstructured":"Novartis AG. Preparation of heterocyclic WDR5 inhibitors as anticancer agents. WO2021026672. 2021."},{"key":"e_1_3_5_103_1","unstructured":"Etern BioPharma (Shanghai) Co. Ltd. Dihydroisoquinolinone derivatives as WDR5 inhibitors and their preparation pharmaceutical compositions and use in the treatment of kabuki syndrome and cancer. WO2022122037. 2022."},{"key":"e_1_3_5_104_1","unstructured":"Elgen Therapeutics Inc. Preparation of low-molecular-weight compound for regulating MLL1-WDR5 interaction and use thereof. WO2023090829. 2023."},{"key":"e_1_3_5_105_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c00195"},{"key":"e_1_3_5_106_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S307113"},{"key":"e_1_3_5_107_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2408889121"},{"key":"e_1_3_5_108_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b01411"},{"key":"e_1_3_5_109_1","unstructured":"Vanderbilt University. Preparation of substituted N-phenyl sulfonamides as WDR5-MYC inhibitors. WO2021021951. 2021."},{"key":"e_1_3_5_110_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c00224"},{"key":"e_1_3_5_111_1","unstructured":"Vanderbilt University. WDR5-MYC inhibitors. WO2021101927. 2021."},{"key":"e_1_3_5_112_1","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.2c00843"},{"key":"e_1_3_5_113_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00371-6"},{"key":"e_1_3_5_114_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c00146"},{"key":"e_1_3_5_115_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abj1578"},{"key":"e_1_3_5_116_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-022-02340-8"},{"key":"e_1_3_5_117_1","unstructured":"Icahn School of Medicine at Mount Sinai & The University of North Carolina at Chapel Hill. WD40 repeat domain protein 5 (WDR5) Degradation\/Disruption compounds and methods of use. US20220348580. 2022."},{"key":"e_1_3_5_118_1","unstructured":"C4 Therapeutics Inc. Tricyclic heterobifunctional compounds for degradation of targeted proteins. US20230372496. 2023."},{"key":"e_1_3_5_119_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm501000a"},{"key":"e_1_3_5_120_1","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.201200306"},{"key":"e_1_3_5_121_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abi4708"},{"key":"e_1_3_5_122_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10565-006-0176-z"},{"key":"e_1_3_5_123_1","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.3c00108"},{"key":"e_1_3_5_124_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0536"},{"key":"e_1_3_5_125_1","unstructured":"Hunan Linecom Medical Technology Co. Ltd. Application of inhibiting combination of TOX3 protein and WDR5 protein in anti-colon cancer drugs. CN116440270. 2023."},{"key":"e_1_3_5_126_1","unstructured":"Huyabio International LLC. Combination therapies with WDR5 protein inhibitors and PD-1 inhibitors for treating cancer. WO2024015478. 2024."}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2024.2441658","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T09:46:29Z","timestamp":1766742389000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2024.2441658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,22]]},"references-count":124,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,2]]}},"alternative-id":["10.1080\/13543776.2024.2441658"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2024.2441658","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,22]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-06-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}